Sangui Biotech International Inc (SGBI) financial statements (2021 and earlier)
Company profile
| Business Address |
352 SOUTH 200 WEST FARMINGTON, UT 84025 |
| State of Incorp. | CO |
| Fiscal Year End | June 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 15 | 21 | 27 | 19 | 36 | 50 | 21 | ||
| Cash and cash equivalents | 15 | 21 | 27 | 19 | 36 | 50 | 21 | ||
| Receivables | 15 | 15 | 35 | ||||||
| Prepaid expense | 17 | 5 | 9 | 4 | 8 | 101 | 21 | ||
| Other undisclosed current assets | 6 | 7 | 28 | 75 | 29 | 60 | |||
| Total current assets: | 53 | 41 | 79 | 51 | 119 | 179 | 102 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 5 | ✕ | ✕ | ✕ | |||||
| Property, plant and equipment | 3 | ||||||||
| Long-term investments and receivables | 3 | 6 | 6 | ||||||
| Long-term investments | 3 | 6 | 6 | ||||||
| Other undisclosed noncurrent assets | (3) | (6) | |||||||
| Total noncurrent assets: | 3 | 5 | 6 | ||||||
| TOTAL ASSETS: | 56 | 46 | 79 | 51 | 125 | 179 | 102 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Debt | 538 | 480 | 478 | ||||||
| Due to related parties | 35 | 30 | 28 | ||||||
| Other undisclosed current liabilities | 128 | 124 | 164 | 529 | 523 | 606 | 453 | ||
| Total current liabilities: | 702 | 634 | 671 | 529 | 523 | 606 | 453 | ||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 702 | 634 | 671 | 529 | 523 | 606 | 453 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (2) | 54 | 49 | (478) | (404) | (426) | (351) | ||
| Common stock | 33,012 | 33,012 | 32,967 | 32,967 | 32,967 | 32,885 | 32,864 | ||
| Treasury stock, value | (19) | (19) | (19) | 19 | 19 | 19 | |||
| Additional paid in capital | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | 4,513 | ||
| Accumulated other comprehensive income | 92 | 94 | 91 | 93 | |||||
| Accumulated deficit | (37,600) | (37,546) | (37,504) | (37,393) | (37,326) | (37,270) | (37,180) | ||
| Other undisclosed stockholders' equity attributable to parent | (586) | (578) | (554) | (661) | |||||
| Stockholders' equity attributable to noncontrolling interest | (644) | (642) | (641) | ||||||
| Total stockholders' equity: | (646) | (588) | (592) | (478) | (404) | (426) | (351) | ||
| TOTAL LIABILITIES AND EQUITY: | 56 | 46 | 79 | 51 | 119 | 179 | 102 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 12 | 0 | 25 | 8 | 44 | 11 | 12 | |
| Cost of revenue (Cost of Goods and Services Sold) | (0) | (0) | (0) | |||||
| Other undisclosed gross profit | 0 | |||||||
| Gross profit: | 12 | 0 | 25 | 8 | 44 | 11 | 12 | |
| Operating expenses | (48) | (56) | (134) | (82) | (104) | (105) | (42) | |
| Other operating expense, net | (3) | |||||||
| Operating loss: | (37) | (56) | (110) | (74) | (60) | (96) | (30) | |
| Nonoperating income (expense) | (19) | 12 | ||||||
| Foreign currency transaction gain (loss), before tax | (15) | 22 | ||||||
| Interest and debt expense | (3) | (3) | (20) | 3 | 3 | 4 | 2 | |
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (5) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (59) | (47) | (135) | (72) | (58) | (92) | (28) | |
| Other undisclosed loss from continuing operations before income taxes | (16) | |||||||
| Loss from continuing operations before income taxes: | (59) | (47) | (135) | (72) | (58) | (92) | (44) | |
| Income tax expense | (1) | (1) | ||||||
| Other undisclosed income from continuing operations | 3 | |||||||
| Loss before gain (loss) on sale of properties: | (59) | (47) | (132) | (73) | (59) | (92) | (44) | |
| Other undisclosed net income (loss) | 3 | 3 | 16 | (4) | 24 | |||
| Net loss: | (55) | (44) | (117) | (73) | (59) | (96) | (20) | |
| Other undisclosed net income (loss) attributable to parent | 1 | 1 | 24 | (1) | (1) | 0 | 8 | |
| Net loss attributable to parent: | (54) | (43) | (93) | (74) | (60) | (96) | (12) | |
| Other undisclosed net income (loss) available to common stockholders, basic | (18) | 8 | 4 | |||||
| Net loss available to common stockholders, diluted: | (54) | (43) | (111) | (66) | (56) | (96) | (12) | |
Comprehensive Income ($ in thousands)
| 12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (55) | (44) | (117) | (73) | (59) | (96) | (20) | |
| Other comprehensive income | 57 | 41 | ||||||
| Other undisclosed comprehensive income | 344 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 2 | (3) | 227 | (73) | (59) | (96) | (20) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.